Three eminent physicists from competing companies and hardware approaches have joined forces to nail down a key concept for ...
Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today ...
Annexon bets on functional outcomes in geographic atrophy & GBS; ARCHER II vision endpoints read out in Q4 2026. Click for ...
Oral Presentations Highlight Phase 2 Vision Protection and Enrollment of a Consistent Phase 3 Patient Population Well-Positioned to Replicate Phase 2 Vision Outcomes ARCHER II is the First Pivotal ...
Immune protection by the complement system depends on C3 cleavage by C3 convertases that is critical to all three activation pathways. Structural data on convertase formation in the classical pathway ...
Unpack the science of the placebo effect and its role in medicine. Discover how the power of belief transforms biology, ...
Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, will present new data from across its portfolio and pipeline at the 2026 American Association ...
By reaching for popular compositions, learners can latch onto their personal interests and find real purpose in their session ...
A global registration path has been established with U.S. and European regulators. ARCHER II is a single protocol that will also be analyzed as two sub-studies after meeting the primary endpoint.
A recent study identified 7 novel variants in the SERPING1 gene and 2 novel variants in the F12 gene associated with HAE.
Complement protein deposition in glomeruli was associated with more frequent relapse and less complete remission in FSGS.
Merge Americas hosts the launch of Florida Quantum, a new initiative to accelerate the state’s quantum economy following the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results